|
|
HIV Update 2002 (9) - SeptemberPublished by: Datamonitor Published: Oct. 22, 2002 - 20 Pages Table of ContentsOverview Introduction The monthly HIV update provides Datamonitor's assessment of the key market events that took place during September 2002. Key events include new product launches, clinical trial data and conference findings. Scope Key events are analyzed in the HIV market during September Gain insight into the likely market impact of the events that took place in September 2002 in the HIV market. Report Highlights Novel pipeline therapeutics eyed to hit the market in 2003-2004 A number of HIV drug manufacturers have pipeline drugs that are anticipated to achieve market approval in the next one to two years. One drug of immediate interest is Roche’s fusion inhibitor, Fuzeon. This drug has attracted substantial patient and physician interest in the last year. However, its complex manufacturing process and expensive raw ingredients will increase its price point. Research concentrates on pediatric HIV treatment Much of the current research on HIV treatment centers around the adult population. However, in attempting to stem the rate of HIV transmission, the emphasis has been placed on the population that willgenerate the greatest revenue. However, there is money to be made on the pediatric and neonatal population. Reasons to Purchase Stay informed of all of the important market led events taking place in the HIV market Gain insight into the likely market impact of the events that took place in September 2002 in the HIV market. DRIVERS AND TRENDS Novel pipeline therapeutics eyed to hit the market in 2003-2004 Research concentrates on pediatric HIV treatment COMPANY HEADLINES A summary of the latest events from a company perspective Triangle Resolves Patent Disputes for Amdoxovir RESEARCH AND DEVELOPMENT HEADLINES A summary of the key events from a pipeline drug perspective Durable Virologic Response for Salvage Patients on Protease Inhibitor-Based Regimens Kaletra Implicated in Causing Cardiovascular Side Effects Roche Submits NDA for Fuzeon (T-20) EU Approval for Saquinavir-Ritonavir Combination DISEASE SPECIFIC HEADLINES An overview of the epidemiological, research and clinical perspective HIV Therapy and Poor Adherence: All the pitfalls, and None of the Benefits Pediatric Response to HAART is Independent of Viral Subtype Lack of Adherence to Neonatal Prophylaxis in Mothers Without Social Support Supervised Treatment Interruption of HIV Treatment May be Effective and Safe Number of Resistance Mutations Can Predict Therapeutic Outcome in Salvage HIV Patients Discontinuation of Successful HAART Results in Gradual Decline in CD4 Levels Genital Wart Risk Increased By HIV in Women with HPV Many CD4 T Cells are HIV-specific in Patients Undergoing HAART Structured treatment interruptions does not improve HIV-specific immune response in chronically infected patients Women May be Able to Delay HIV Therapy Until CD4 Counts Reach 200 Copies/ml Use of Nonoxynol-9 May Increase Risk of HIV Transmission EMERGING MARKETS HEADLINES A summary of the key events from the emerging markets Generic AIDS drug approved in China HIV and AIDS Rates Skyrocketing in Eastern Europe AbstractIntroduction: The monthly HIV update provides Datamonitor's assessment of the key market events that took place during September 2002. Key events include new product launches, clinical trial data and conference findings. Scope: * Key events are analyzed in the HIV market during September * Gain insight into the likely market impact of the events that took place in September 2002 in the HIV market. Report Highlights: Novel pipeline therapeutics eyed to hit the market in 2003-2004 A number of HIV drug manufacturers have pipeline drugs that are anticipated to achieve market approval in the next one to two years. One drug of immediate interest is Roche's fusion inhibitor, Fuzeon. This drug has attracted substantial patient and physician interest in the last year. However, its complex manufacturing process and expensive raw ingredients will increase its price point. Research concentrates on pediatric HIV treatment Much of the current research on HIV treatment centers around the adult population. However, in attempting to stem the rate of HIV transmission, the emphasis has been placed on the population that willgenerate the greatest revenue. However, there is money to be made on the pediatric and neonatal population. Reasons to Purchase: * Stay informed of all of the important market led events taking place in the HIV market * Gain insight into the likely market impact of the events that took place in September 2002 in the HIV market.Get Full Details About This Report >> |
|
|||
|
About MarketResearch.com
|
||||